![Thomas O. Hecht](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thomas O. Hecht
Président chez
AFFIMED N.V.
Fortune : 15 M $ au 31/05/2026
Profil
Thomas O.
Hecht was the founder of HHC consulting, founded in 2002, and Cell Medica Switzerland AG, founded in 2009, where Dr. Hecht served as Executive Chairman from 2014 to 2016.
Current jobs include Chairman-Supervisory Board at Affimed NV since 2007, Chairman-Supervisory Board at Affimed AG since 2005, Chairman at Orion Biotechnology Canada Ltd. since 2019, Chairman-Supervisory Board at Affimed GmbH since 2007, Chairman at Aelix Therapeutics SL since 2017, Independent Director at BioInvent International AB since 2020, and President & Director at Haemosan, Inc. Former jobs include Chairman & Chief Executive Officer at Telormedix SA from 2009 to 2011, Executive Chairman at Cytos Biotechnology AG from 2003 to 2012, Chairman at ESBATech, a Novartis Co. GmbH from 2004 to 2009, Chairman at Vaximm AG from 2016 to 2020, Chairman at Lipideon Biotechnology AG, Chairman-Supervisory Board at SuppreMol GmbH from 2008 to 2015, Director at The Caisse de dépôt et placement du Québec, Independent Director at IBEX Technologies, Inc., Director at Société Générale de Financement du Québec, Non-Executive Director at Kuur Therapeutics Ltd. from 2017 to 2020, Director at Humabs BioMed SA from 2013 to 2017, Co-Head-Bone Marrow Transplantation Program at the University of Freiburg, and Vice President-Marketing at Amgen (Europe) GmbH from 1989 to 2002.
Education includes a doctorate from the University of Freiburg, graduate studies at McGill University, and undergraduate studies at Sir George Williams University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
Haivision Systems, Inc.
 Haivision Systems, Inc. Computer PeripheralsElectronic Technology Manufactures and sells video streaming products 11,89 % | 13/03/2026 | 3 268 352 ( 11,89 % ) | 15 M $ | 31/05/2026 |
Postes actifs de Thomas O. Hecht
| Sociétés | Poste | Début |
|---|---|---|
| AFFIMED N.V. | Président | 01/01/2007 |
| BIOINVENT INTERNATIONAL AB | Directeur/Membre du Conseil | 03/07/2020 |
Orion Biotechnology Canada Ltd.
 Orion Biotechnology Canada Ltd. BiotechnologyHealth Technology Operates as biotechnology company | Président | 12/11/2019 |
Affimed GmbH
 Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Provides business and private economic services | Président | 01/01/2007 |
Aelix Therapeutics SL
 Aelix Therapeutics SL BiotechnologyHealth Technology Develops novel vaccines to cure HIV infection | Président | 01/08/2017 |
Affimed AG | Président | 01/01/2005 |
Haemosan, Inc.
 Haemosan, Inc. Regional BanksFinance Operates as bank holding company, through its subsidiaries provides banking services | President | - |
Anciens postes connus de Thomas O. Hecht
| Sociétés | Poste | Fin |
|---|---|---|
Vaximm AG
 Vaximm AG Miscellaneous Commercial ServicesCommercial Services Develops immunotherapies for cancer treatment | Président | 30/06/2020 |
Kuur Therapeutics Ltd.
 Kuur Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops cell immunotherapies for treatment of solid and hematological malignancies | Président | 07/12/2017 |
| ░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░ ░░░░░░░░░░░ ░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Thomas O. Hecht
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
66
Relations au 1er degré
24
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 24 |
|---|---|
The Caisse de dépôt et placement du Québec
 The Caisse de dépôt et placement du Québec Investment ManagersFinance CDPQ uses constructive capital to create new opportunities and position businesses for success – in private equity, equity markets, private credit, infrastructure and real estate. Each asset class has a specific risk-return profile and brings together various specialized portfolios and mandates. These are composed of liquid and less liquid securities and are managed in an integrated manner mainly internally. They are convinced that sustainable investing is a fundamental vector of long-term returns. | Finance |
IBEX Technologies, Inc.
 IBEX Technologies, Inc. Pharmaceuticals: OtherHealth Technology Produces proprietary enzymes and reagents for diagnostic tests | Health Technology |
Affimed NV
 Affimed NV Pharmaceuticals: MajorHealth Technology Discovers and develops antibody-based therapeutic drugs | Health Technology |
Société Générale de Financement du Québec
 Société Générale de Financement du Québec Investment ManagersFinance With a focus on the long-term economic growth of Québec and its different regions, Société Générale de Financement du Québec (SGF) targets projects that promise highly profitability in the following sectors: agrifood, chemicals, petrochemicals, plastics and energy, forest products, health and high technology. They also look to invest in industrial logistics, machinery, metals and minerals, recreotourism and transportation. SGF's aim is to support economic development projects in cooperation with private partners, and in accordance with accepted requirements for profitability and the policies of the government of Québec | Finance |
BioInvent International AB
 BioInvent International AB BiotechnologyHealth Technology Develops and manufactures immunomodulatory antibodies for cancer treatment | Health Technology |
University of Freiburg
 University of Freiburg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cytos Biotechnology AG
 Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Discovers and develops new protein drugs and innovative therapeutic concepts | Commercial Services |
McGill University
 McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ESBATech, a Novartis Co. GmbH
 ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services Develops antibody fragment therapeutics | Commercial Services |
Sir George Williams University
 Sir George Williams University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
SuppreMol GmbH
 SuppreMol GmbH Pharmaceuticals: MajorHealth Technology Develops novel therapeutics for the treatment of autoimmune diseases | Health Technology |
Kuur Therapeutics Ltd.
Kuur Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops cell immunotherapies for treatment of solid and hematological malignancies | Health Technology |
Telormedix SA
 Telormedix SA Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases | Health Technology |
Cell Medica Switzerland AG
 Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Researches, develops, manufactures, and distributes pharmaceutical, biological, medical, and diagnostic products | Health Technology |
Amgen (Europe) GmbH
 Amgen (Europe) GmbH BiotechnologyHealth Technology Manufactures human therapeutics | Health Technology |
Vaximm AG
Vaximm AG Miscellaneous Commercial ServicesCommercial Services Develops immunotherapies for cancer treatment | Commercial Services |
Haemosan, Inc.
Haemosan, Inc. Regional BanksFinance Operates as bank holding company, through its subsidiaries provides banking services | Finance |
Lipideon Biotechnology AG
 Lipideon Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Researches and develops treatment of arteriosclerosis and related cardiovascular diseases | Commercial Services |
Humabs BioMed SA
 Humabs BioMed SA Miscellaneous Commercial ServicesCommercial Services Develops human monoclonal antibodies for treatment of infectious and inflammatory diseases | Commercial Services |
HHC consulting | |
Affimed AG | |
Aelix Therapeutics SL
Aelix Therapeutics SL BiotechnologyHealth Technology Develops novel vaccines to cure HIV infection | Health Technology |
Orion Biotechnology Canada Ltd.
Orion Biotechnology Canada Ltd. BiotechnologyHealth Technology Operates as biotechnology company | Health Technology |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Provides business and private economic services | Commercial Services |
